PROK - PROKIDNEY CORP.
IEX Last Trade
1.76
-0.015 -0.852%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.78
-0.02
-0.85%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
17.88%
1 Month
-2.73%
3 Months
-13.59%
6 Months
-20.18%
1 Year
-12.32%
2 Year
-71.06%
Key data
Stock price
$1.76
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.23 - $4.44
52 WEEK CHANGE
-$16.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Timothy A. Bertram
Region: US
Website: prokidney.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: prokidney.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Recent news